Algernon Pharmaceuticals Stock News

Algernon Pharmaceuticals Inc announced that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on its investigation of NP-120 (Ifenprodil) for the treatment of small c

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) shares are scheduled to reverse split before the market opens on Wednesday, November 24th. The 1-100 reverse split was announced on Wednesday, November 24th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, November 24th. AGNPF stock opened at $0.04 on Friday. Algernon Pharmaceuticals []

VANCOUVER, BC / ACCESSWIRE / November 19, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Algernon Pharmaceuticals discussing their latest press release.

(PR-inside.com) VANCOUVER, BC / ACCESSWIRE / November 19, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Algernon Pharmaceuticals discussing their latest press release. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company''s latest press release through exclusive insights and interviews with company executives. Algernon (CSE:AGN) announces positive feedback on its planned Phase 1/2a DMT Human Stroke Study Algernon (AGN) has received positive feedback from the United Kingdom Medicines and Healthcare Products Regulatory Agency. The feedback was related to the company''s planned Phase ..

VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the Company or Algernon) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency (UK MHRA). The scientific advice meeting was related to the Companys planned Phase 1/2a stroke study with AP-188 (N,N-dimethyltryptamine or DMT), a known psychedelic compound that is part of the tryptamine family.

Drug repurposing model reduces risk and capital required Working to develop Ifenprodil for idiopathic pulmonary fibrosis and chronic cough Experienced management team What Algernon Pharmaceuticals doe

Algernon Pharmaceuticals Inc revealed that it has had a positive meeting with UK regulator, the MHRA, and aims to file a clinical trial authorisation (CTA) application for a  Phase 1/2a study of DMT

Toronto, Ontario--(Newsfile Corp. - Le 18 novembre/November 2021) Algernon Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) po

VANCOUVER, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (Algernon or Company) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical development company, announces that it intends to consolidate its Class A common shares (the Common Shares) on a one-hundred (100) to one (1) basis (the Consolidation). The Company currently

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the target of a significant growth in short interest in the month of October. As of October 29th, there was short interest totalling 1,200 shares, a growth of 200.0% from the October 14th total of 400 shares. Based on an average daily trading volume, of 474,000 shares, the short-interest ratio []

Algernon Pharmaceuticals Inc told investors it continued to advance towards a Phase 1 clinical trial of DMT to treat stroke, as the company unveiled more positive pre-clinical data from an in vitro st

Algernon Pharmaceuticals Inc. said it has recently received a C$2 million cash payment from a refundable tax credit program from its clinical research work in Australia, which brings its current work

Algernon Pharmaceuticals Inc said it has filed a scientific advice meeting request with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for a Phase 1/2a stroke study with its DMT-bas

Algernon Pharmaceuticals Inc said it had filed a pre-Investigational New Drug (IND) meeting request with the US Food and Drug Administration (FDA) over its repurposed drug Ifenprodil for chronic cough

VANCOUVER, British Columbia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmace